

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Medical Technologies Advisory Committee (MTAC)

69th MTAC Meeting – Friday 26th May 2017

Level1A City Tower, Piccadilly Plaza, Manchester M1 4BT

Committee members present: Dr Peter Groves (Chair)
Dr Fiona Denison (Vice-chair)
Ms Susan Bennett
Mr Mike Burrows
Mr Matthew Campbell – Hill
Professor Daniel Clark
Mr Steven Fearn
Professor Tony Freemont
Professor Shaheen Hamdy
Dr Cynthia Iglesias
Dr Greg Irving
Professor Mohammad Ilyas
Professor Eva Kaltenthaler
Dr Paul Knox
Dr Avril McCarthy
Dr Karen McCutcheon
Dr Jai Patel
Mr Brian Selman
Mr Andrew Thorpe
Professor Allan Wailoo
Mr John Wilkinson
Mr Alun Williams

Committee member apologies: Professor Rory O'Connor
Dr Amber Young

Medical Technologies Evaluation Programme staff in attendance: Mirella Marlow, Programme Director
Mark Campbell, Associate Director
Chris Pomfrett, Technical Adviser
Bernice Dillon, Technical Adviser
Sheryl Warttig, Technical Adviser
David Sissling, Senior Project Consultant
Joanne Higgins, Senior Technical Analyst
Kimberley Carter, Technical Analyst
Liesl Millar, Technical Analyst
Jae Long, Project Manager
Izabela Syrek, Administrator

Expert Advisers in attendance:	Dr Dominic Harrington, Scientific Director at St. Thomas' Hospital / Consultant Clinical Scientist and Reader in Diagnostic Haematology at King's College London - via phone
	Prof Matthew Costa, Professor of Orthopaedic Trauma Survey and Honorary Consultant Trauma Surgeon, John Radcliffe Hospital in Oxford, Oxford University Hospitals NHS Foundation Trust - via phone
Observers in attendance:	Elaine Chesworth, Medical Technology Implementation Manager, Adoption team, NICE
	Jane Lynn, Business Analyst, Resource Impact Assessment team, NICE
	Rachel Gick, Information Specialist, Guidance Information Services team, NICE
	Tara Chernick, Analyst, Adoption and Impact team, NICE
	Juan Carlos Rejon-Parrilla, Senior Analyst, Science Policy and Research Programme, NICE

10:00 – Part 2 closed session commenced

1. Introduction to the meeting

The chairman welcomed all members of the committee and other attendees present to the meeting.

2. Any other business

No other business was offered.

3. Minutes of previous meeting

The Chairman noted one minor correction to the minutes from the 17th March 2017 committee meeting. These were amended following the meeting for publication on the NICE website.

4. MT338 Active-B12 assay for diagnosis of vitamin B12 status

The chairman welcomed the invited expert to the meeting.

The chairman asked all committee members, experts, NICE staff and observers to declare any relevant interests in relation to the technology being considered.

- Mr Steven Fearn declared a personal financial interest as he is employed by Abbott who is a manufacturer of a competing product to the technology being considered.

- It was agreed that his declaration would prevent Mr Fearn from participating in this section of the meeting and he was asked to leave the room.
- Dr Dominic Harrington declared a personal financial interest as he is the Scientific Director of Viapath, a joint venture majority owned by the NHS (Guy's, St. Thomas' and King's College Hospital) with Serco.

Dr Harrington has not undertaken any fee-paid work commissioned by the commercial healthcare sector during the previous 12 months but will be giving a paid presentation about the value of Active B12 in June 2017 in Athens, Greece, as part of a session sponsored by Abbott at the IFCC EuroMedLab 'Approaches to Achieve Measurably Better Healthcare Performance'.

- It was agreed that his declaration would not prevent Dr Harrington from participating in this section of the meeting.

No further conflicts of interest were declared for the technology.

The committee was asked if there were any specific equality issues to consider in relation to the technology.

The topic was introduced by Prof Allan Wailoo with Dr Dominic Harrington providing expert advice.

The committee then considered the technology for selection and routing. The selection and routing decision was reached by consensus.

5. MT331 The Feeling Good app for depression

The chairman asked all committee members, NICE staff and observers to declare any relevant interests in relation to the technology being considered.

- Dr Peter Groves (Chair) declared a personal specific non-financial conflict of interest, in that a close family member is currently developing an application. Once completed, the application would be regarded as a competitor to the technology under consideration.
 - It was agreed that his declaration would prevent Dr Groves from participating in this section of the meeting and he left the room. The consideration of this technology was therefore chaired in his absence by the vice-chair Dr Fiona Denison.
- Dr Fiona Denison declared a personal non-financial interest as she is currently participating in a research project (independent grant funded) developing a web-based computerised CBT application for pregnant women with mild depression and anxiety.
 - It was agreed that her declaration would not prevent Dr Denison from participating in this section of the meeting.

- Prof Eva Kaltenthaler declared a personal non-financial interest as she was a lead author on an economic analysis for one of the comparators (CCBT).
 - It was agreed that her declaration would not prevent Prof Kaltenthaler from participating in this section of the meeting.

No further conflicts of interest were declared for the technology.

The committee was asked if there were any specific equality issues to consider in relation to the technology.

The topic was introduced by Mr Brian Selman with expert advice provided in advance of the meeting.

The committee then considered the technology for selection and routing. The selection and routing decision was reached by consensus.

12:00 – 12:20 – Break

12:20 – Meeting reassumed

6. MT337 Galaxy UNYCO for temporary stabilisation of lower limb fractures

The chairman asked all committee members, NICE staff and observers to declare any relevant interests in relation to the technology being considered.

- Prof Matthew Costa declared a non-personal financial interest as his institution (University of Oxford) holds research grants in relation to musculoskeletal trauma but not relating to the device under consideration.
 - It was agreed that his declaration would not prevent Prof Costa from participating in this section of the meeting.

No further conflicts of interest were declared for the technology.

The committee was asked if there were any specific equality issues to consider in relation to the technology.

The topic was introduced by Dr Greg Irving with Prof Matthew Costa providing expert advice.

The committee then considered the technology for selection and routing. The selection and routing decision was reached by consensus.

13:15 – 13:50 – Lunch

13:50 – Meeting resumed

7. MT336 The IN.PACT drug-coated balloon for peripheral arterial disease

The chairman asked all committee members, NICE staff and observers to declare any relevant interests in relation to the technology being considered.

- Mr Steven Fearn declared a specific personal financial interest as he is employed by Abbott who is a manufacturer of related products in the area of the technology being considered.
 - It was agreed that his declaration would prevent Mr Fearn from participating in this section of the meeting and he was asked to leave the room.
- Mr Andrew Thorpe declared a personal financial interest as Mr Thorpe had been in receipt of an educational grant from the manufacturer of the technology under consideration. The grant was received 3 years prior to the meeting and involved a visit to a unit for educational purposes relating to sacral nerve stimulation.
 - It was agreed that his declaration would not prevent Mr Thorpe from participating in this section of the meeting.
- Dr Jai Patel declared a potential future non-personal financial interest as Dr Patel is planning to approach the manufacturer of the technology under consideration for a departmental educational grant in the near future. This grant would be intended to help fund conference attendance by staff in Dr Patel's department.
 - It was agreed that his declaration would not prevent Mr Patel from participating in this section of the meeting.

No further conflicts of interest were declared for the technology.

The committee was asked if there were any specific equality issues to consider in relation to the technology.

The topic was introduced by Prof Eva Kaltenthaler with expert advice provided in advance of the meeting.

The committee then considered the technology for selection and routing. The selection and routing decision was reached by consensus.

8. MT335 Microcuff subglottic suctioning endotracheal tubes for airway management

The chairman asked all committee members, NICE staff and observers to declare any relevant interests in relation to the technology being considered.

- Prof Daniel Clark declared a non-personal financial interest as one of his teams is supporting a research project run by Nottingham University to develop a new ET tube. The key research element is that they are developing novel fibre optic sensors to measure and monitor physiological

parameters (particularly, blood flow, oxygenation, pressure) on the cuff with a view to reduce tissue damage and onward clinical detriment. This is early scientific research and the manufacturer of the technology under consideration is involved.

- It was agreed that his declaration would not prevent Prof Clark from participating in this section of the meeting.

No further conflicts of interest were declared for the technology.

The committee was asked if there were any specific equality issues to consider in relation to the technology.

The topic was introduced by Dr Paul Knox with expert advice provided in advance of the meeting.

The committee then considered the technology for selection and routing. The selection and routing decision was reached by consensus.

9. Date of the next meeting

The next meeting of the Medical Technologies Advisory Committee will be held on Friday 16th June 2017 and will start promptly at 10:00am. The meeting will be held at the NICE Manchester offices, Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BT.

14:45 – Meeting ended